Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer

Hu, JL; Zheng, ZN; Lei, J; Cao, YX; Li, QY; Zheng, Z; Chen, CJ

Zheng, ZN (corresponding author), Nanchang Univ, Jiangxi Canc Hosp, Dept Pharm, Nanchang 330029, Jiangxi, Peoples R China.

PPAR RESEARCH, 2021; 2021 ():

Abstract

Enhancer of zeste homolog 2 (EZH2) is abnormally highly expressed in pancreatic cancer (PC). However, it is not ideal to treat PC by inhibiting EZH2. ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索